Vancouver, BC – June 16th, 2023 – Syniad Innovations Inc. (“Syniad”) is pleased to announce its latest investment in the advanced Artificial Intelligence (AI) platform of OxReGen Inc. (“OxReGen”), marking a significant milestone in OxRegen’s self-driving lab ambition. This groundbreaking initiative aims to revolutionize the landscape of drug discovery by connecting chemistry & biology at the scale necessary for successful AI drug discovery.
Traditional AI models often excel at performing well on benchmark datasets but struggle to translate those successes into the real-world discovery of safe and effective drugs. Self-driving lab initiatives represent a solution to this challenge, bridging the gap between AI capabilities and in vivo drug development.
OxReGen is the result of the collective expertise of three visionary co-founders. Stephen Davies, professor emeritus and former head of the Department of Chemistry at the University of Oxford, brings a wealth of knowledge and applied experience at the intersection of chemistry, biology and drug discovery. Jussi Westergren, scientific director of the Emmy Network, an AI and social network dynamics institute hosted at Keble College Oxford, contributes invaluable insights into AI and causal network dynamics. Florent Chandelier is an accomplished technology and innovation leader, recognized for his entrepreneurial achievements in delivering AI products and solutions to the healthcare and pharmaceutical industries.
John Davies, Syniad’s CEO, commented, “It’s great to see Syniad spread its wings to help support pre-eminent science of international provenance. This is a project that lies right at the heart of our matter + simulation investment thesis, originated by founders with a phenomenal inventive record”.
Florent Chandelier, co-founder and CEO of OxReGen said: “We are excited to announce our partnership with Syniad as we work together to realize our ambitious vision of a self-driving lab that revolutionizes medicine and drives innovation in drug discovery. With Syniad’s unwavering commitment to creating value through a distinct approach, combining quantum technologies, AI cognition, and biomimetic technologies, we have found the perfect ally to bring our ground-breaking ideas to life.”
For more information or media inquiries, contact:
CEO, Syniad Innovations
About Syniad Innovations
Syniad’s mission is to transform breakthrough research into globally significant companies, to address major societal and environmental challenges. It was founded in Vancouver in 2016 on the basis of a purpose-driven investment thesis weighted towards the intersection of advanced computation (simulation) and novel chemistries (matter). Our philosophy is to proactively engage with world-class researchers much earlier than traditional sources of capital.
Oxregen is a seed-stage forward-thinking technology company focused on extending healthy lives by enhancing the regenerative ability of the body. With an immediate goal to build a self-driving lab that integrates AI-driven hypothesis testing with robotics, OxReGen aims to enable the discovery of safe and effective drugs from biology-driven data insights.
About OxReGen co-founders
Stephen Davies, professor emeritus at the University of Oxford and formerly head of the Department of Chemistry. During Steve’s illustrious career, he held the Waynflete Professorship, one of the most distinguished chairs in UK academia. He was an early proponent of university research commercialization, having created Oxford Asymmetry International plc, which was acquired for £316m in 2000. Recently, Professor Steve Davies received the 2021 Royal Society Mullard Award in recognition of his long and successful record in converting brilliant academic ideas to commercial successes with world impact in the biotech sector.
Jussi Westergren is the Scientific Director of the Emmy Network, an AI and social network dynamics institute hosted at Keble College Oxford and the University of Turku, in Finland. His research focus is the scope and limitations of modelling nature with a variety of applications in artificial intelligence, computing, life sciences and modelling of social systems. Apart from his research efforts, Jussi has played a key role in founding and advising several companies like academia.edu, DeepMind and Intellectual Ventures. He has a lifelong commitment to philanthropy and has been involved in major international projects that include the Turkana Basin Institute and the African Institute of Mathematical Science.
Florent Chandelier has a unique entrepreneurial expertise at the intersection of platform technologies, AI innovation, and regulatory constraints governing personal data and healthcare products in North America, Asia and Europe. He has assembled multidisciplinary teams of engineers, scientists and clinicians, built and deployed big data platforms across hospital information systems and enterprise environments, and empowered healthcare professionals with software medical devices. Florent has repeatedly managed technology-driven commercial deals and collaborations, from seed to delivery, to actively drive corporate growth at Cadens Medical Imaging, Imagia and Imagia Canexia Health.